Gastroenterology

Your daily dose of the clinical news you may have missed.

The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.

Your daily dose of the clinical news you may have missed.

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

The updated guidelines include 19 recommendations related to the diagnosis and management of eosinophilic esophagitis.

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

Your daily dose of the clinical news you may have missed.

Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.

ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Submission based on results from the phase 3 QUASAR induction study, which showed statistically significant and clinically meaningful improvements in symptoms.

Your daily dose of the clinical news you may have missed.

AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.

Histologic inflammation was associated with reduced fertility whether IBD disease was active or quiescent in a nationwide study of Swedish women aged 15 to 44 years.

Budesonide oral suspension is the first oral therapy for EoE and represents a needed option in the category, offering flexibility for both patients and clinicians.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Already high rates of readmission and mortality at 30 days rose significantly higher at 90 days, according to this National Readmissions Database review.

Unplanned emergency service and medication utilization make up the majority of costs of IBD care, reported researchers.

Among more than 1.5 million persons hospitalized for COVID-19, a history of Crohn disease or ulcerative colitis significantly increased risk for poor outcomes.

Survey findings presented at the Crohn’s & Colitis Congress suggest a need for education among some health care specialists about the clinical presentation of ulcerative colitis.

"A meaningful percentage" of individuals with Crohn disease are treated during maintenance with biologic doses ≥20%higher than recommended in FDA labeling.

A 10-second check of your GI IQ.

Findings showed a high incidence of outpatient Clostridioides difficile infection despite a low rate of testing.

When does management of Crohn disease warrant assessment of C-reactive protein and fecal calprotectin and when is endoscopy indicated? Test your IBD IQ.

Your daily dose of the clinical news you may have missed.

Findings showed that IBD phenotype varied by race, although foreign-born participants of all races showed evidence of later onset and milder disease.